C12N 2770/32311
Enterovirus
C12N2770/32311 (Enterovirus) appears on 124 US grants and 183 published applications in this corpus.
Search patents in C12N- Granted patents
- 124
- Published applications
- 183
- Assignees
- 127
- Inventors
- 448
- Latest grant
- 23 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 2 | 0 |
| 2000 | 6 | 0 |
| 2001 | 3 | 1 |
| 2002 | 2 | 3 |
| 2003 | 2 | 3 |
| 2004 | 1 | 5 |
| 2005 | 0 | 1 |
| 2006 | 1 | 5 |
| 2007 | 3 | 4 |
| 2008 | 3 | 4 |
| 2009 | 2 | 4 |
| 2010 | 1 | 8 |
| 2011 | 2 | 3 |
| 2012 | 8 | 9 |
| 2013 | 1 | 8 |
| 2014 | 4 | 3 |
| 2015 | 3 | 14 |
| 2016 | 2 | 13 |
| 2017 | 6 | 9 |
| 2018 | 10 | 13 |
| 2019 | 14 | 15 |
| 2020 | 9 | 11 |
| 2021 | 3 | 9 |
| 2022 | 7 | 11 |
| 2023 | 6 | 9 |
| 2024 | 5 | 9 |
| 2025 | 9 | 5 |
| 2026 | 3 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2770/32334Use of virus or viral component as vaccineIndexing code58
- C12N 2770/32351Methods of production or purification of viral materialIndexing code27
- C12N 2770/32332Use of virus as therapeutic agent, other than vaccineIndexing code25
- C12N 2770/32322New viral proteins or individual genes, new structural or functional aspects ofIndexing code23
- C12N 2770/32361Methods of inactivation or attenuationIndexing code21
- C12N 2770/32321Viruses as suchIndexing code19
- C12N 2770/32341Use of virus, viral particle or viral elements as a vectorIndexing code14
- C12N 2770/32371Demonstrated in vivo effectIndexing code14
Recent patents
- Constructs and methods for preparing circular RNA23 Jun 2026US 12,662,671 B2Peking University
- Click outer membrane vesicles16 Jun 2026US 12,653,882 B2Intravacc B.V.
- Optimized oncolytic viruses and uses thereof13 Jan 2026US 12,521,424 B2Sator Therapeutics
- Antitumor virus30 Dec 2025US 12,508,291 B2Shanxi Academy of Advanced Research and Innovation
- Pharmaceutical composition containing stabilized nucleic acid adjuvant11 Nov 2025US 12,465,644 B2Sml Biopharm Co., Ltd.
- Compositions and methods for improved protein translation from recombinant circular rnas13 Aug 2026US 2026/0234654 A1The Board of Trustees of the Leland Stanford Junior University
- Method for separating and purifying cvb123 Apr 2026US 2026/0109955 A1Hangzhou Yangshengtang Biopharma Co., Ltd.
- Bivalent inactivated ev71-ca16 vaccine, method for preparing the same, and use thereof12 Mar 2026US 2026/0069673 A1Aim Action Biopharm Co., Ltd
- Chimeric invasin system5 Mar 2026US 2026/0062730 A1SiVEC Biotechnologies LLC
- Coxsackievirus B Compositions and Methods Of Use Thereof20 Nov 2025US 2025/0352634 A1Vactech Oy
Most cited
By later US patents
- Recombianant Hepatitis a virus59US 5,294,548 AAmerican Biogenetic Sciences, Inc. · 1994
- Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds39US 8,524,676 B2Sarepta Therapeutics, Inc. · 2013
- Screening method for chronic immune dysfunction syndrome35US 5,426,028 ARush-Presbyterian-St. Luke's Medical Center · 1995
- Broad-spectrum antivirals against 3C or 3C-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses35US 9,474,759 B2Kansas State University Research Foundation · 2016
- Screening kit and method for diagnosing chronic immune dysfunction syndrome34US 5,538,856 AThe Regents of the University of California · 1996